A large amount of research evidence supports the potential benefits of the proposed clinical application of an “off-the-shelf”, cryopreserved allo-hBM-MSC therapy to patients receiving a full-thickness corneal transplant following a loss of the previous corneal transplant to the same (corneal re-transplant) – a circumstance that is associated with greatly increased risk for acute rejection and long-term transplant failure.

The Benefits: The potential benefits are reduced frequency of acute rejection, reduced requirement for prolonged immunosuppressive drugs and their accompanying side effects and increased likelihood of long-term function transplantation.